17 results about "Tracheitis" patented technology

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention belongs to the field of biological medicine, and particularly relates to application of small molecules in prevention and treatment of acute and chronic bronchitis, N-dodecyl methylamine can significantly prolong cough latency time of mice suffering from acute or chronic bronchitis, significantly reduce cough times of the mice suffering from acute or chronic bronchitis, and significantly improve cough latency time of the mice suffering from acute or chronic bronchitis. The micromolecule can be used as a medicine for treating or relieving acute or chronic bronchitis, and a new choice is provided for clinical treatment of bronchitis; double distilled water suspension small molecules are adopted for administration, the method is simple, convenient and rapid, and a remarkable effect is achieved. The micromolecule can obviously reduce the cough frequency and cough latency time of acute and chronic bronchitis, and has a good clinical application prospect.

The invention discloses a human-derived anti-respiratory syncytial virus neutralizing antibody RS414 and application of the human-derived anti-respiratory syncytial virus neutralizing antibody RS414. The antibody RS414 is obtained by screening by using a phage surface presentation technology. The antibody specifically recognizes the respiratory syncytial virus particle antigen, aims at the F protein of the respiratory syncytial virus, has obvious enzyme-linked immunosorbent assay reaction with the respiratory syncytial virus, and has a neutralizing activity function of resisting respiratory syncytial virus infection. The antibody provided by the invention can be prepared into a specific antibody drug for preventing and treating respiratory syncytial virus infection, and can be used for clinically preventing or treating lower respiratory tract infection, especially severe lower respiratory tract infection (pneumonia and capillary bronchitis) caused by the respiratory syncytial virus.

The invention relates to prevention and control of infectious bovine rhinotracheitis, in particular to an infectious bovine rhinotracheitis subunit vaccine and a preparation method thereof. The invention provides an infectious bovine rhinotracheitis subunit vaccine, which comprises a gD recombinant protein with an amino acid sequence as shown in SEQ ID NO: 3 and a gB recombinant protein with an amino acid sequence as shown in SEQ ID NO: 4. The infectious bovine rhinotracheitis subunit vaccine can effectively inhibit the replication level of IBRV in a body and obviously relieve clinical symptoms caused by IBRV infection, and has a wide application prospect in prevention and control of infectious bovine rhinotracheitis.

The invention discloses an internal traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, and the traditional Chinese medicine for pulmonary fibrosis comprises 28-31 g of bletilla striata, 9-11 g of donkey-hide gelatin, 9-11 g of astragalus membranaceus and 4-6 g of pseudo-ginseng. Therefore, the invention provides the traditional Chinese medicine composition for internal use as well as the preparation method and the application thereof, and the traditional Chinese medicine composition for internal use is used for treating chronic gastritis, gastroduodenal ulcer complicated with perforation bleeding; chronic tracheitis, bronchiectasis and bleeding; the traditional Chinese medicine composition has good prevention and treatment effects on both pulmonary fibrosis and lithiasis.

The application optimizes the antigen component of the bovine contagious nasal tracheitis inactivated vaccine, and prepares a new bovine contagious nasal tracheitis inactivated vaccine, which can produce high level of neutralizing antibody after immunizing the bovine; the safety of the vaccine is improved through the suspension culture process promotion and the inactivation agent, adjuvant screening and purification process promotion. The safety and efficacy test results show that: after the bovine is immunized by using the inactivated vaccine, no adverse reaction is produced, and high level of neutralizing antibody is produced. The results show that the immunization effect of the bovine contagious nasal tracheitis inactivated vaccine can be improved by using the application.

This invention provides a traditional Chinese medicine composition, characterized in that the composition comprises: 0.5-1 parts by weight of honey-processed ephedra, 0.5-1.5 parts by weight of bitter almond, 0.5-1 parts by weight of perilla seed, 1.5-3 parts by weight of mulberry bark, 1.5-2 parts by weight of scutellaria, 0.5-1.5 parts by weight of cicada slough, 0.5-1.5 parts by weight of silkworm, 1.5-3 parts by weight of earthworm, 0.5-1.5 parts by weight of angelica root, 0.5-1.5 parts by weight of belamcanda rhizome, 1.5-3 parts by weight of coltsfoot flower, 0.5-1.5 parts by weight of prepared pinellia tuber, and 0.5-1 parts by weight of licorice root. This invention provides a traditional Chinese medicine composition that works synergistically to relieve lung congestion and asthma, suppress cough, clear heat, and resolve phlegm. Modern pharmacological experiments have shown that this composition can be used to treat bronchial asthma or its chronic persistent phase, bronchitis with cough, and pharyngitis.

This invention relates to a one-tube colorimetric LAMP primer composition, kit, and applications for detecting feline infectious rhinotracheitis virus (FLVR), belonging to the field of molecular biology technology. It solves the problems of existing PCR and qPCR-based infectious disease detection methods, which require complex and expensive temperature control equipment, demand highly skilled operators, have long detection times, and are unsuitable for on-site point-of-care testing. The primer composition of this invention includes an outer primer, an inner primer, and a loop primer. The outer primer consists of an upstream primer F3 and a downstream primer B3; the inner primer consists of an upstream primer FIP and a downstream primer BIP; and the loop primer consists of an upstream primer LF and a downstream primer LB, with sequences shown in SEQ ID NO. 1-6, respectively. This primer composition provides rapid detection, high specificity, a detection limit comparable to qPCR, excellent repeatability and stability, requires no specialized equipment, allows for visual result interpretation, and is suitable for on-site point-of-care testing.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition with anti-inflammatory and cough-relieving effects and a preparation method. The traditional Chinese medicine composition provided by the invention comprises a main medicine and an auxiliary medicine, the main medicine is prepared from nauclea officinalis, radix stemonae and pericarpium citri reticulatae; wherein the weight part of the nauclea officinalis is greater than or equal to the total weight part of the radix stemonae and the pericarpium citri reticulatae; the adjuvants comprise a first adjuvant and a second adjuvant; the first adjuvant is platycodon grandiflorum; the second adjuvant is selected from one or more of ceylon leucas herb, radix asteris, liquorice and / or honey ephedra. The invention provides a new traditional Chinese medicine formula core component with a definite and efficient inflammation eliminating effect, the nauclea officinalis, the radix stemonae and the pericarpium citri reticulatae are used as main materials, respiratory tract infection inflammations such as trachitis, bronchitis and sphagitis and cough symptoms caused by the respiratory tract infection inflammations can be relieved on the basis of eliminating the inflammations, and meanwhile the traditional Chinese medicine composition has high safety.

The invention is suitable for the technical field of gene engineering, and provides gD + mi3 protein nanoparticles for preventing and treating IBR and a preparation method and application thereof.The gD + mi3 protein nanoparticles are formed by coupling gD-st fusion protein and mi3-sc fusion protein, and gD antigens of infectious bovine rhinotracheitis viruses are displayed on the surfaces of the mi3 protein nanoparticles through isopeptide bonds; the amino acid sequence of the mi3 protein nanoparticle is shown as SEQ ID NO: 6 in a sequence table; the amino acid sequence of the gD-st fusion protein is as shown in a sequence table SEQ ID NO: 2; the amino acid sequence of the mi3-sc fusion protein is shown as SEQ ID NO: 4 in a sequence table. After animals are immunized by the gD + mi3 protein nanoparticles, an effective immune protection effect can be generated, and the gD + mi3 protein nanoparticles have a good application prospect in prevention and control of infectious bovine rhinotracheitis caused by IBRV (infectious bovine rhinotracheitis virus).

To provide a method for treating bronchiolitis in infants.SOLUTION: The method comprising repeatedly administering to the infant a gas mixture comprising nitric oxide in a concentration of about 144 to about 176ppm for a first period of time, followed by a gas mixture that does not include nitric oxide for a second period of time; The administration is repeated for a time sufficient to a) reduce the length of hospitalization required to achieve 92% or greater oxygen saturation in room air, b) reduce the length of hospitalization required to achieve a clinical score of 5 or less, c) reduce the length of hospitalization required to discharge from hospital, or d) any combination thereof, as compared to an infant not subjected to the repeated administration of nitric oxide.SELECTED DRAWING: Figure 1

The invention is applicable to the technical field of genetic engineering, and provides a gD-mi3 fusion protein of infectious bovine rhinotracheitis virus and a preparation method and application thereof, the gD-mi3 fusion protein is formed by fusing a mi3 tag sequence with a gD genome of the infectious bovine rhinotracheitis virus; the amino acid sequence of the mi3 tag sequence is as shown in a sequence table SEQ ID NO: 4; the amino acid sequence of the gD-mi3 fusion protein is shown as SEQ ID NO: 2 in a sequence table. After animals are immunized by the gD-mi3 fusion protein, an effective immune protection effect can be generated, and the gD-mi3 fusion protein has a good prevention and control application prospect on infectious bovine rhinotracheitis caused by the IBRV virus.

Provided in the present invention are an anti-RSV antibody and the use of the anti-RSV antibody in the preparation of a drug for preventing or treating RSV infections or symptoms or diseases related thereto, wherein the RSV infections comprise subtype A and subtype B infections and upper respiratory tract RSV infections and / or lower respiratory tract RSV infections, and the symptoms or diseases related to RSV infections comprise fevers, coughs, sore throats, runny noses, and dyspnea, bronchitis or pneumonia caused by RSV infections.

A method of treating COPD, Asthma, Pneumonia, Bronchitis, Cystic Fibrosis, Pulmonary Edema, Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis and PAH in a patient. One embodiment includes administering a vasodilator prostacyclin analogue, such as Beraprost or Iloprost, separately or together with a form of Diethylcarbamazine or Zileuton. Other embodiments may include fluvoxamine. The vasodilator prostacyclin analogue is inhaled. Diethylcarbamazine / Zileuton is inhaled into the lung or administered orally or intravenously. Other embodiments include fluvoxamine. This treatment reduces the progression of the disease, reduces life-threatening exacerbations, and improves the quality of life. The treatment is also for COPD patients with eosinophilia who are incompletely treated with steroids and addresses steroid-unresponsive disease components of COPD including pulmonary hypertension and intravascular inflammation and bronchiectasis. The treatment may include a PDE4 inhibitor and current treatments with existing steroids and beta-adrenergic receptor agonists and / or muscarinic receptor blockers. The treatment is also for ARDS and COVID-19.